Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Payables (2016 - 2025)

Bio-Techne has reported Payables over the past 16 years, most recently at $26.3 million for Q4 2025.

  • Quarterly results put Payables at $26.3 million for Q4 2025, down 20.69% from a year ago — trailing twelve months through Dec 2025 was $26.3 million (down 20.69% YoY), and the annual figure for FY2025 was $25.3 million, down 33.34%.
  • Payables for Q4 2025 was $26.3 million at Bio-Techne, down from $30.2 million in the prior quarter.
  • Over the last five years, Payables for TECH hit a ceiling of $38.0 million in Q2 2024 and a floor of $24.1 million in Q4 2022.
  • Median Payables over the past 5 years was $29.1 million (2021), compared with a mean of $29.2 million.
  • Biggest five-year swings in Payables: skyrocketed 47.86% in 2024 and later crashed 33.34% in 2025.
  • Bio-Techne's Payables stood at $26.8 million in 2021, then dropped by 9.93% to $24.1 million in 2022, then soared by 30.76% to $31.5 million in 2023, then rose by 5.1% to $33.1 million in 2024, then fell by 20.69% to $26.3 million in 2025.
  • The last three reported values for Payables were $26.3 million (Q4 2025), $30.2 million (Q3 2025), and $25.3 million (Q2 2025) per Business Quant data.